Since April 2018, Nucleic Acid Testing (NAT) using Polymerase Chain Reaction (PCR) technology is being used for identifying Hepatitis B and Hepatitis C viruses on every single donor in addition to CLIA which was already being performed. Thus fulfilling FDA (USA) requirement for donor screening.